46,812 Shares in MiMedx Group, Inc. (NASDAQ:MDXG) Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets purchased a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 46,812 shares of the company's stock, valued at approximately $450,000.

A number of other large investors also recently added to or reduced their stakes in MDXG. First Light Asset Management LLC acquired a new position in shares of MiMedx Group during the 4th quarter worth approximately $32,168,000. Norges Bank acquired a new position in shares of MiMedx Group in the fourth quarter valued at $4,020,000. JPMorgan Chase & Co. increased its holdings in shares of MiMedx Group by 133.1% in the fourth quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company's stock valued at $6,668,000 after purchasing an additional 395,739 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in MiMedx Group by 484.2% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company's stock valued at $3,487,000 after buying an additional 300,433 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in MiMedx Group by 18.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock valued at $17,360,000 after buying an additional 280,327 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other MiMedx Group news, CEO Joseph H. Capper purchased 200,000 shares of the stock in a transaction on Friday, May 2nd. The stock was acquired at an average price of $6.34 per share, with a total value of $1,268,000.00. Following the transaction, the chief executive officer now directly owns 529,530 shares of the company's stock, valued at approximately $3,357,220.20. This trade represents a 60.69% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO William Frank Iv Hulse sold 54,596 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the completion of the transaction, the chief accounting officer now owns 440,178 shares of the company's stock, valued at approximately $3,473,004.42. The trade was a 11.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 141,907 shares of company stock worth $1,112,580. 1.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Wall Street Zen downgraded MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 9th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th.

MiMedx Group Trading Down 1.5%

MDXG traded down $0.10 during trading on Friday, hitting $6.46. The company's stock had a trading volume of 54,982 shares, compared to its average volume of 688,382. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14. The stock's fifty day moving average price is $6.97 and its 200-day moving average price is $8.14. The firm has a market capitalization of $953.42 million, a P/E ratio of 11.73 and a beta of 1.85.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.06. The business had revenue of $88.21 million during the quarter, compared to the consensus estimate of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.